{"id":43692,"date":"2025-10-17T15:51:10","date_gmt":"2025-10-17T07:51:10","guid":{"rendered":"https:\/\/flcube.com\/?p=43692"},"modified":"2025-10-17T15:51:10","modified_gmt":"2025-10-17T07:51:10","slug":"sinclairs-maili-precise-receives-nmpa-acceptance-notice-for-class-iii-device","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43692","title":{"rendered":"Sinclair\u2019s MaiLi\u202fPrecise Receives NMPA Acceptance Notice for Class\u202fIII Device"},"content":{"rendered":"\n

Sinclair (Hangzhou) Medical Technology Co., Ltd.<\/strong>, a wholly\u2011owned subsidiary of Huadong Medicine<\/strong> (SHE: 000963<\/a>), announced that it has received an Acceptance Notice<\/strong> from the National Medical Products Administration (NMPA)<\/strong> for the registration application of MaiLi\u202fPrecise<\/strong>, a Class\u202fIII medical device. The product is a cross\u2011linked sodium hyaluronate gel formulated with lidocaine for injection, designed to provide an immediate correction of infra\u2011orbital hollows.<\/p>\n\n\n\n

Product Highlights<\/h2>\n\n\n\n
Feature<\/th>Detail<\/th><\/tr><\/thead>
Device Class<\/strong><\/td>Class\u202fIII medical device<\/td><\/tr>
Active Ingredient<\/strong><\/td>Cross\u2011linked sodium hyaluronate gel + lidocaine<\/td><\/tr>
Concentration<\/strong><\/td>Lowest sodium hyaluronate concentration in the MaiLi series<\/td><\/tr>
Clinical Benefit<\/strong><\/td>Immediate correction of infra\u2011orbital hollows post\u2011injection<\/td><\/tr>
Regulatory Status<\/strong><\/td>Acceptance Notice from NMPA (Oct\u202f16\u202f2025)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

MaiLi Series Overview<\/h2>\n\n\n\n